Cargando…
Inhibiting the immunoproteasome's β5i catalytic activity affects human peripheral blood‐derived immune cell viability
Small molecule inhibitors selectively targeting the immunoproteasome subunit β5i are currently being developed for the treatment of autoimmune disorders. However, patients carrying loss‐of‐function mutations in the gene encoding β5i (Psmb8) suffer from the proteasome‐associated autoinflammatory synd...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6581949/ https://www.ncbi.nlm.nih.gov/pubmed/31236277 http://dx.doi.org/10.1002/prp2.482 |